Comparative efficacy of HIV regimens
Executive Summary
Highly-active antiretroviral therapy regimens that include non-nucleoside reverse transcriptase inhibitors were "modestly" better at virological suppression than protease inhibitor-based regimens, according to a direct meta-analysis of 12 trials conducted by the Oregon Evidence-based Practice Center. No difference was seen in death or disease progression or in withdrawal due to adverse events. However, the findings were complicated by an indirect analysis of 14 trials that included trials that were not head-to-head comparisons, which showed that NNRTI-based HAART was worse than PI-based regimens for virological suppression. The authors suggest that "indirect comparisons could be particularly unreliable for complex and rapidly evolving interventions such as HAART"...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.